Vera Therapeutics (VERA) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Zymeworks (ZYME) has outperformed Vera Therapeutics (VERA) over the past year, gaining 8.8% versus a loss of 10.6%. Over five years, ZYME leads with a +34.1% price change compared with -15.2% for VERA. Vera Therapeutics is the larger company by market cap ($1.84 billion vs $1.81 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | VERA | ZYME |
|---|---|---|
| Share price | $25.45 | $26.14 |
| Market cap | $1.84B | $1.81B |
| 1-day change | -4.86% | -2.68% |
| YTD return | -49.74% | -0.72% |
| 1-year return | -10.58% | +8.83% |
| 5-year return | -15.17% | +34.05% |
| P/E ratio (TTM) | — | 49.32 |
| Forward P/E | — | 54.95 |
| EPS (TTM) | $-5.90 | $0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $105.97M |
| Revenue growth (YoY) | — | +38.87% |
| Net income (latest FY) | $-299.62M | $-81.13M |
| Operating margin | — | -87.34% |
| Net margin | — | -76.56% |
| 52-week high | $56.05 | $31.97 |
| 52-week low | $25.08 | $21.52 |
| Distance from 52-week high | -54.59% | -18.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +180.39% | +65.61% |
| Average volume | 1.95M | 1.09M |
| Shares outstanding | 72.30M | 68.70M |
| Employees | 362 | 279 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZYME has outperformed VERA by 19.4 percentage points over the past year.
About Vera Therapeutics
VERA stock →Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 362 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 279 employees
VERA vs ZYME FAQ
Which is bigger, Vera Therapeutics or Zymeworks?
Vera Therapeutics (VERA) is larger, with a market capitalization of $1.84B compared with $1.81B for Zymeworks (ZYME).
Which stock has performed better over the past year, VERA or ZYME?
ZYME returned +8.83% over the past 12 months, compared with -10.58% for VERA (price return, excluding dividends). Past performance does not predict future results.
Are Vera Therapeutics and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.